Impact on cognitive function-are all statins the same?
Dementia is a major public health concern, affecting an estimated 7% of the population over 65 and 30% over 80 years of age. There is mounting evidence in the literature from meta-analyses of high-quality prospective cohort studies that statins may have a positive impact in reducing the incidence of dementia. Little is known, however, on whether certain types of statins are more impactful than others. This narrative review specifically explores the various properties of different statin types and whether these differences lead to a clinically significant differential impact on cognitive function. We critically evaluate the literature, emphasizing interesting and important new findings, and overall aim to bring the reader up-to-date on evidence-based recommendations.
Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA.
Nishant P
NP
Shah
Kristopher J
KJ
Swiger
Seth S
SS
Martin
D000367:Age Factors; D050197:Atherosclerosis / Q000188:drug therapy*; D003071:Cognition / Q000187:drug effects*; D003704:Dementia / Q000453:epidemiology / Q000503:physiopathology / Q000517:prevention & control; D014943:Global Health; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D015994:Incidence; D011379:Prognosis
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors